AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02525510 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pump Eligible - Normothermia - Pump Both Kidneys
Description: Normothermia and Machine Perfusion Deceased Donors will be kept normothermic (36.5-37.5 C) prior to organ recovery. Recovered kidneys will receive machine perfusion prior to implantation.OPO's protocol
Study NCT02525510 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pump Eligible - Hypothermia and Pump Right Kidney
Description: Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery. Right Kidney will receive machine perfusion prior to implantation and the Left Kidney will receive cold storage.~Recovered kidneys will be placed in University of Wisconsin for cold storage until reimplantation.
Study NCT02525510 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pump Eligible - Hypothermia and Pump Left Kidney
Description: Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery. Left Kidney will receive machine perfusion prior to implantation and the Right Kidney will receive cold storage.
Study NCT02525510 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Not Pump Eligible - Normothermia
Description: Deceased Donors will be kept normothermic (36.5-37.5 C) prior to organ recovery.~Pulsatile Perfusion of kidney grafts based on the respective OPO's protocol
Study NCT02525510 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Not Pump Eligible - Hypothermia
Description: Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery.
Study NCT01595321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (Cy) 200 mg/m\^2 administered one day prior to GVAX (day 0). One dose will be given prior to SBRT and FOLFIRINOX and four additional doses after FOLFIRINOX completion for a total of 5 doses. Additional CY/GVAX boosts may be given every 6 months thereafter until disease recurrence.
Study NCT01595321 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVAX Pancreas Vaccine
Description: GVAX administered one day after Cy (day 1). One dose will be given prior to SBRT and FOLFIRINOX and four additional doses after FOLFIRINOX completion for a total of 5 doses. Additional CY/GVAX boosts may be given every 6 months thereafter until disease recurrence.
Study NCT01595321 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation
Description: Cohort 1 and 2: SBRT (6.6 Gy per day, 33 Gy total dose) will be administered over 5 days within 6-10 weeks of pancreas surgery (Whipple).~Cohort 3: SBRT (6.6 Gy) will be administered over 5 days starting between 13-17 days after the first dose of CY/GVAX.
Study NCT00047034 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00047034 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02083978 — intervention group
Intervention type: OTHER
Intervention: MRI scanning
Study NCT01595321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: FOLFIRINOX is given over six 28-day cycles, starting at least 1 weeks after SBRT.~FOLFIRINOX consists of the following drugs given IV on days 1 and 15 of each cycle:~Oxaliplatin (85 mg/m\^2), Irinotecan (180 mg/m\^2), Leucovorin (400 mg/m\^2), Fluorouracil (400 mg/m\^2 bolus followed by 2,400 mg/m\^2 continuous infusion over 46-48 hours);~modified FOLFIRINOX consists of the same regimen described above but without the 400 mg/m\^2 Fluorouracil bolus.
Study NCT04263545 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group session with smoking cessation counsellor
Description: Group session with smoking cessation counsellor
Study NCT04263545 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard Care
Description: standard care arm will receive very brief advice (VBA) and signposting to local organisations to support a quit.
Study NCT04789798 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TeleDiab (Telemedicine)
Description: TeleDiab program components consist of:~1. Electronic transmission of capillary blood glucose measurement results~2. Electronic transmission of blood pressure measurements~3. Synchronized video-conferencing, secure messaging~4. Access to clinical data from patient files when necessary~5. Reminding of routine follow-up tests and examinations~6. Providing web-based educational materials to patients.
Study NCT04789798 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual diabetes care, as provided by primary care providers
Study NCT00515450 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB-0998 (Intravenous immunoglobulin)
Study NCT00515450 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plasmapheresis
Study NCT00824369 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: No drug will be administered
Description: No drug will be administered.
Study NCT03163433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback in the consultation
Description: Patients will complete electronic Patient Reported Outcome Measures (PROM) before the consultation at the hospital. The results are fed back to physicians. In the consultation patients will systematically participate in a dialogue with their physician about issues that are most important for the patients.
Study NCT03766711 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Repetitive bimanual task training for upper limb motor function recovery.
Study NCT04661527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Treatment with Sarilumab 200 mg IV x 2 doses 24 hours apart for first 5 patients. If no severe AE and no significant improvement within 48 hours, the dose will be increased for subsequent patients to 400 mg IV for the first dose and 200 mg or 400 mg IV for the second dose 24 hours later. Te second dose will be decided at the investigators discretion.
Study NCT00410579 — intervention group
Intervention type: OTHER
Intervention: Telephone interview
Description: Telephone interview to assess generic health status, quality of life, comorbidity, impact of cancer, use of medical services, health rating, pain, fatigue, activities of daily living, demographics, functional well-being(C-06 only), and neurotoxicity (C-07 only)
Study NCT01832727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oprozomib
Description: Oprozomib tablets were supplied containing 60, 90, or 120 mg of oprozomib. Oprozomib extended release tablets were supplied containing 150, 180, 210, 240, or 270 mg of oprozomib. Both formulations were administered in a single dose on dosing days. The tablet formulation required multiple tablets to reach each dose on dosing days.
Study NCT03750942 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adhesix® monofilament polypropylene mesh (Bard Davol)
Description: The intervention group will receive preventive mesh placement and in the control group no mesh is placed, the stoma is closed according to standard practise.
Study NCT01334320 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: elective neck dissection
Description: patient underwent elective neck dissection as initial treatment, along with the excision of the primary tumor
Study NCT02156609 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous ventricular support with the HeartMate PHP
Description: The HeartMate PHP device will be inserted percutaneously prior to the start of high risk coronary interventions (complex disease, reduced ejection fraction, etc.) to provide hemodynamic support,
Study NCT00270803 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tetra Hydro Cannabinol (THC)
Description: Oral THC 13mg and 17mg smoked in low nicotine cigarettes
Study NCT03207568 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thoracic Endovascular Aortic Repair (TEVAR)
Description: thoracic endovascular repair (TEVAR) with a thoracic stent-graft
Study NCT02750800 — intervention group
Intervention type: BIOLOGICAL
Intervention: Adalimumab
Description: Pre-filled syringe or pen, administered by subcutaneous injection
Study NCT04016025 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adherence to topical standard therapy assessed
Description: Adherence defined as percentage of patients applying at least aimed daily dose
Study NCT02008084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRIA-662
Description: Following Baseline randomized to active TRIA-662 2 x 500 mg tablets, three times daily with meals for 2 weeks and then active TRIA-662 2 x 1000 mg tablets, three times daily with meals for 12 weeks.
Study NCT02008084 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: TRIA-662
Description: Following Baseline randomized to active TRIA-662 2 x 500 mg tablets, three times daily with meals for 2 weeks and then active TRIA-662 2 x 1000 mg tablets, three times daily with meals for 12 weeks.
Study NCT02008084 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Following Baseline randomized to placebo TRIA-662 2 x 500 mg tablets, three times daily with meals for 2 weeks and then placebo TRIA-662 2 x 1000 mg tablets, three times daily with meals for 12 weeks.
Study NCT02008084 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Following Baseline randomized to placebo TRIA-662 2 x 500 mg tablets, three times daily with meals for 2 weeks and then placebo TRIA-662 2 x 1000 mg tablets, three times daily with meals for 12 weeks.
Study NCT02881944 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low FODMAP Diet
Description: Diet low in foods containing Fermentable Oligo-, Di-, and Mono-saccharides and Polyols
Study NCT02881944 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High FODMAP Diet
Description: Typical diet of foods containing Fermentable Oligo-, Di-, and Mono-saccharides and Polyols
Study NCT00786942 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: high tibial osteotomy
Description: addition of bone graft to fill the osteotomy gap
Study NCT00786942 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: higi tibial osteotomy
Description: the gap of the tibia is unfilled
Study NCT00327665 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 11-valent pneumococcal vaccine GSK513026
Description: Two-dose intramuscular injection. Each group receiving one of the 3 formulations
Study NCT02750800 — intervention group
Intervention type: BEHAVIORAL
Intervention: AbbVie Care 2.0
Description: Supportive services provided to participants included reminder calls, emails, text messages, nursing services, dietician, and psychological support. An adalimumab starter pack, injection guide, digital and print educational materials were also provided.
Study NCT00142519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Upon the 1st request for analgesic medication morphine 2 mg, upon the 2nd request for analgesic medication morphine 2 mg
Study NCT00142519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methadone and morphine
Description: Upon the 1st request for analgesic medication morphine 2 mg, upon the 2nd request for analgesic medication morphine 1 mg and methadone 1 mg
Study NCT00620321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2181308 sodium
Description: 750 milligrams (mg) is administered as a 3-hour intravenous infusion on Days 1, 2, 3, 8, 15, 22 of Cycle 1 (28 days) and Days 1, 8, 15, 22 of Cycle 2 (28 days) until disease progression or unacceptable toxicity develops.
Study NCT00620321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 1.5 grams per square meter (g/m²) will be administered as a 4-hour intravenous infusion on Days 3, 4, 5 of Cycle 1 (28 days) and Days 1, 2, 3 of Cycle 2 (28 days) until disease progression or unacceptable toxicity develops.
Study NCT00620321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: 12 milligrams per square meter (mg/m²) will be administered as a 30-minute intravenous infusion on Days 3, 4, 5 of Cycle 1 (28 days) and on Days 1, 2, 3 of Cycle 2 (28 days) until disease progression or unacceptable toxicity develops.
Study NCT00606762 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy is performed at either 8 mm Hg or 12 mm Hg intra-abdominal pressure
Study NCT00632463 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RI-001
Description: Dose 1
Study NCT00632463 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RI-001
Description: Dose 2
Study NCT00632463 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: RI-001
Description: Placebo
Study NCT03010995 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prazosin
Description: Prazosin will used to study the mechanism involved in nicotine induced acute cardiovascular changes
Study NCT03010995 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prazosin
Description: Prazosin will used to study the mechanism involved in nicotine induced acute cardiovascular changes
Study NCT02804880 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HAR
Description: Smokers will be introduced to various smoking cessation (SC) services in Hong Kong (using the referral card) and be motivated to use the services. Field research staff will assist on-site booking SC services for smokers. Tailored messages, including: harm of smoking, benefit of smoking cessation, importance of adherence to smoking cessation appointment and encouragement on abstinence will be sent via instant messaging (IM) services (e.g. WhatsApp, WeChat) to smokers after initial contact.
Study NCT02804880 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LTM
Description: Fix-schedule SMS messages will be sent to encourage them to book the smoking cessation services appointment. Smokers are required to book the SC appointments by themselves.
Study NCT02804880 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AWARD
Description: Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again: to repeat the intervention during tel. follow-ups.
Study NCT02804880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Referral card
Description: The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans.
Study NCT02804880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A4 leaflet
Description: The 2-side color printed A4 leaflet, which systematically covers the most important messages to motivate smoking cessation
Study NCT02804880 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief advice
Description: Very brief, minimal and general smoking cessation advice
Study NCT02804880 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 12-page booklet
Description: 12-page smoking cessation self-help booklet
Study NCT03572439 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Sensory block level check using ice
Description: Patients are asked to report when the ice feels as cold as it does on the forehead.
Study NCT02563288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol
Description: effect of esmolol on intraoperative sympathetic control and on extubation conditions.
Study NCT02563288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: effect of dexmedetomidine on intraoperative sympathetic control and on extubation conditions.
Study NCT02197039 — intervention group
Intervention type: DRUG
Intervention: esomeprazole or pantoprazole
Description: Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis is achieved spontaneously or by gastroscopy. Patients then receive a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Because of concern for patient safety with certain drug-drug interactions, patients who take clopidogrel receive intravenous pantoprazole (Pantoloc®, Takeda, Singen, Germany), including an 80 mg loading dose and a 3-day continuous high-dose (8 mg/h) of infusion.
Study NCT02197039 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic hemostasis
Description: At the index gastroscopy, bleeding ulcers are checked. If the adherent clot is found over the ulcer base, it will be vigorously washed away with water jet. All of the stigmata of recent hemorrhage (SRH) are treated by one or a combination of endoscopic therapies including local injection of diluted epinephrine 1:10000, bipolar heated probe at 20 J per goal consecutively until achievement of coaptive coagulation, argon plasma coagulation, band ligation, or hemoclip therapy. The success of endoscopic hemostasis is defined as cessation of bleeding together with achievement of cavitation at the vessel after application of the heater probe.
Study NCT01205672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 850 mg by mouth once daily for at least 7 days, and up to 30 days before surgery.
Study NCT03272945 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Linked-color imaging
Description: Linked-color imaging colonoscopy
Study NCT03272945 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Linked-color imaging
Description: Linked-color imaging colonoscopy
Study NCT03121222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: The antioxidant group received orally two N-acetylcysteine tablets (each tablet contained 600 mg of NAC; Lamberts Health Care Ltd, Kent, United Kingdom). The participants were instructed to receive the capsules every twelve hours in order to achieve high concentration of N-acetylcysteine throughout the 24 h. Each individual received the capsules pre-packed in daily doses labeled with the day of consumption. The supplementation period was 30-day for N-acetylcysteine.
Study NCT03121222 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose
Description: The placebo group received orally two lactose tablets per day. The participants were instructed to receive the capsules every twelve hours. Each individual received the capsules pre-packed in daily doses labeled with the day of consumption. The supplementation period was 30-day for placebo.
Study NCT03007953 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Palliative Care
Description: Care delivered by a nurse, including symptom assessment and management, patient education on lung cancer and treatment options, discussion and communication about preferences for care, psychosocial assessment (including referrals to ancillary services), and patient-centered resources. A personalized treatment plan based on the patient's lung cancer stage, treatment, symptoms and psychosocial needs will be developed by the palliative care team (physician, study nurse) with input from the patient and family member. The study nurse will assess patient's symptoms, implement and monitor the treatment plan applying established End-of- Life Nursing Education Consortium (ELNEC) for Veterans protocols.
Study NCT02123160 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child Parent Psychotherapy (CPP)
Description: Child Parent Psychotherapy (CPP) is a multi-theoretical approach to enhance the caregiver-child relationship in the context of the caregiver's psychiatric history (e.g., depression) and/or caregiver/child exposure to traumatic events. Mother and child's in-session interactions are used to provide developmental guidance, and reinforce reciprocity between parent and child, affect regulation , continuity in daily living, and helping mother and child understand themselves and each other in the context of the maternal psychiatric functioning and/or familial exposure to trauma. When there is a history of trauma exposure for mother and/or child, mother and child create a joint narrative of the trauma, identify and address traumatic triggers, and focus on safety issues.
Study NCT02123160 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control (usual treatment)
Description: Following Time 1 (pre-treatment) assessment, mother-child patient dyads randomized to the control group will be referred to usual treatment in the community for psychoeducation, counseling/ therapy for maternal depressive symptoms, and child behavioral/ emotional difficulties. Control patient dyads will be closely monitored through regular contact with the study research assistant and follow up by a licensed study clinician to assess mother/ child's psychiatric functioning and make necessary referrals to alternative treatments or arrange an emergency evaluation, if needed.
Study NCT02898207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study NCT02898207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onalespib
Description: Given IV
Study NCT01449591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BFH772 1% ointment
Study NCT01449591 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle ointment
Study NCT01449591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Noritate® 1% cream
Study NCT00626912 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endovascular coil embolization
Description: standard endovascular coil embolization with or without adjunct techniques